What is TriNetX?
Founded in 2013, TriNetX operates as a global health research network dedicated to accelerating discoveries through the generation of real-world evidence. The company leverages real-time access to longitudinal clinical data, combined with advanced analytics, to empower researchers to address complex questions with unprecedented speed. TriNetX's platform is instrumental in transforming how clinical research is conducted, enabling faster insights and more efficient drug development pipelines.
How much funding has TriNetX raised?
TriNetX has raised a total of $53M across 2 funding rounds:
Series A
$13M
Series D
$40M
Series A (2014): $13M with participation from MPM Capital, ITOCHU, Mitsui & Co, and Deerfield
Series D (2019): $40M, investors not publicly disclosed
Key Investors in TriNetX
MPM Capital
MPM Capital is a venture capital firm known for its focus on the life sciences sector, investing in companies that aim to transform healthcare through innovative therapies and technologies.
ITOCHU
ITOCHU Corporation is a Japanese general trading company with diverse business interests, including significant investments in healthcare and technology sectors, seeking to foster growth and innovation.
Deerfield
Deerfield Management is a healthcare-focused investment firm that provides capital and strategic support to companies advancing medical innovation and improving patient outcomes.
What's next for TriNetX?
With its substantial enterprise-level backing, TriNetX is strategically positioned for accelerated growth and expanded market penetration. The company's focus on real-world evidence and data analytics in healthcare is increasingly critical, suggesting future investments will likely target further platform enhancements, broader data network integration, and the development of new analytical tools. This sustained capital infusion signals confidence in TriNetX's model to drive innovation within the clinical research and pharmaceutical sectors, potentially leading to new strategic partnerships and a wider adoption of its platform by research institutions and life sciences companies.
See full TriNetX company page
